Pajjiż: Irlanda
Lingwa: Ingliż
Sors: HPRA (Health Products Regulatory Authority)
DOMPERIDONE
McNeil Healthcare (Ireland) Ltd
A03FA03
DOMPERIDONE
10 Milligram
Film Coated Tablet
Product not subject to medical prescription
Propulsives
Authorised
2009-12-04
FACE 1 turn over ▶ PACKAGE LEAFL ET: INFORMATION FOR THE USER domperidone MOTILIUM ® 10 mg Film Coated Tablets This medicine is subject to additional monitoring. This will allow quick identifi cation of new safety information. You can help by reporting any side eff ects you may get. See the end of section 4 for how to report side eff ects. READ ALL OF THIS LEAFL ET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leafl et or as your doctor or pharmacist have told you. ■ Keep this leafl et. You may need to read it again. ■ Ask your pharmacist if you need more information or advice. ■ If you get any side eff ects, talk to your doctor or pharmacist. This includes any possible side eff ects not listed in this leafl et. See section 4. ■ You must talk to a doctor if you do not feel better or if you feel worse after 7 days. WHAT IS IN THIS LEAFL ET 1. What Motilium 10mg Tablets are and what it is used for 2. What you need to know before you take Motilium 10mg Tablets 3. How to take Motilium 10mg Tablets 4. Possible side eff ects 5. How to store Motilium 10mg Tablets 6. Contents of the pack and other information 1. WHAT MOTILIUM 10MG TABLETS ARE AND WHAT IT IS USED FOR This medicine is used to treat nausea (feeling sick) and vomiting (being sick) in adults and adolescents, 12 years of age and older and weighing 35kg or more. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MOTILIUM 10MG TABLETS DO NOT TAKE MOTILIUM 10MG TABLETS IF YOU: ■ are allergic (hypersensitive) to domperidone or any of the other ingredients of Motilium 10mg Tablets ■ have stomach bleeding or if you regularly have severe abdominal pain or persistent black stools ■ have a blocked or perforated gut ■ have a tumour of the pituitary gland (prolactinoma) ■ have a moderate or severe liver disease ■ have an ECG (electrocardiogram) that shows a heart problem called “prolonged QT interval” ■ have or had a problem where your heart Aqra d-dokument sħiħ
SUMMARY OF PRODUCT CHARACTERISTICS This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1 NAME OF THE MEDICINAL PRODUCT Motilium 10mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains domperidone 10mg. Excipients with known effect: Each film-coated tablet contains 54.2mg of lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White to faintly cream-coloured, circular biconvex tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Motilium Tablets are indicated for the relief of the symptoms of nausea and vomiting. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Motilium Tablets should be used at the lowest effective dose for the shortest duration necessary to control nausea and vomiting. It is recommended to take Motilium Tablets before meals. If taken after meals, absorption of the drug is somewhat delayed. Patients should try to take each dose at the scheduled time. If a scheduled dose is missed, the missed dose should be omitted and the usual dosing schedule resumed. The dose should not be doubled to make up for a missed dose. Usually, the maximum treatment duration should not exceed one week. Adults, and adolescents (12 years of age and older and weighing 35kg or more): One 10mg tablet up to three times per day with a maximum dose of 30mg per day. Use in children under 12 years of age (and adolescents weighing less than 35kg): Not recommended Patients > 60 years of age: Patients older than 60 years of age should consult a healthcare professional before taking Motilium. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Aqra d-dokument sħiħ